Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a...

Full description

Saved in:
Bibliographic Details
Published inNeurology Vol. 58; no. 9; p. 1418
Main Authors Kompoliti, K, Adler, C H, Raman, R, Pincus, J H, Leibowitz, M T, Ferry, J J, Blasucci, L, Caviness, J N, Leurgans, S, Chase, W M, Yones, L C, Tan, E, Carvey, P, Goetz, C G
Format Journal Article
LanguageEnglish
Published United States 14.05.2002
Subjects
Aged
Antiparkinson Agents - pharmacokinetics
Area Under Curve
Benzothiazoles
Biological Availability
Carbidopa - pharmacology
Dose-Response Relationship, Drug
Drug Interactions
Enzyme Inhibitors - pharmacology
Female
Humans
Levodopa - pharmacokinetics
Male
Parkinson Disease - drug therapy
Postmenopause
Pramipexole
Sex Factors
Thiazoles - pharmacokinetics
Online AccessGet more information

Cover

More Information
Summary:The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.
ISSN:0028-3878
DOI:10.1212/WNL.58.9.1418